Revvity to Acquire Human Cell Design for Metabolic Drug Discovery
WALTHAM, Mass. — September 9, 2026 Revvity, Inc. announced that it has entered into a definitive agreement to acquire...
Rare Pediatric Disease
Advertisement
Quoin Pharmaceuticals Gains FDA Pediatric Designation for QRX003
ASHBURN, Va. — September 8, 2026 Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Scholar Rock Advances Apitegromab FDA Review with Second Fill-Finish Facility
CAMBRIDGE, Mass., August 7, 2026 Scholar Rock announced that the U.S. Food and Drug Administration (FDA) review of its...
Galibra Neuroscience Wins FDA Designations for SSADH Therapy
Boston, Massachusetts, August 5, 2026 Galibra Neuroscience has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation...
Phoenix Nest Secures $2.98M to Advance JLK-247 Gene Therapy
Brooklyn, New York, August 5, 2026 Phoenix Nest Inc. has been awarded a $2,984,658 Small Business Innovation Research (SBIR)...
Advertisements
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
Saol Therapeutics Advances SL1009 in FDA Review
ROSWELL, Ga., DUBLIN, Ireland, and HAMILTON, Bermuda, July 28, 2026 Saol Therapeutics has announced that the U.S. Food and...
Ionis Reaches Phase 3 Enrollment Milestone for Obudanersen
CARLSBAD, Calif., July 6, 2026 Ionis Pharmaceuticals announced the completion of enrollment for the pivotal pediatric cohort of its...
Opus Genetics Secures FDA Alignment for Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., July 6, 2026 Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has...
RedHill’s Opaganib Gains FDA Rare Pediatric Disease Status
RALEIGH, North Carolina, USA & TEL AVIV, Israel – June 9, 2026 RedHill Biopharma has received a significant regulatory...
Advertisement
